Kanilad

Lacosamide, the active ingredient in Kanilad, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy. GNH USA supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is used to manage seizure disorders that involve focal neuronal hyper‑excitability. - Partial‑onset seizures: reduces seizure frequency when used as adjunctive therapy. - Focal seizures: helps achieve better seizure control in combination with other antiepileptics. - Refractory focal epilepsy: provides an additional option for patients not responding adequately to first‑line agents.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: increased tiredness or lack of energy. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate cranial pain. - Blurred vision: temporary visual disturbances. - Diplopia: double vision.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive or suicidal ideation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmia: alterations in heart rhythm, including PR‑interval prolongation. - Respiratory depression: reduced breathing effort, especially with CNS depressants. - Allergic reactions: anaphylaxis or severe hypersensitivity.

Before initiating therapy, consider patient‑specific factors and safety measures. - Renal impairment: adjust dosing or monitor renal function closely. - Hepatic impairment: evaluate liver function and consider dose modification. - Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation. - Concomitant CNS depressants: monitor for additive sedation or respiratory effects. - Pregnancy considerations: use only if potential benefit justifies potential risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin): may markedly lower lacosamide levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase lacosamide exposure. - Other antiepileptics (e.g., valproate): may require dose adjustments. - Alcohol: can enhance central nervous system depression. - Drugs that prolong PR interval (e.g., digoxin): monitor cardiac conduction.